Immunovia AB 2023 SR
The report outlines Immunovia's sustainability approach for the 2023 fiscal year, focusing on Public Welfare, Sustainable Products, and a Sustainable Workplace. Following a significant restructuring and the withdrawal of its IMMray PanCan-d test, the company is now focused on developing a next-generation blood test for early pancreatic cancer detection. Immunovia emphasizes collaboration with external partners and research centers to advance its diagnostic capabilities. The report also highlights the company's commitment to ethical business practices and alignment with the UN Sustainable Development Goals.
Company: Immunovia AB
Sector: Professional & technical services
Country: Sweden
Year: 2023
Type: SR
Pages: 5
Back to company
Immunovia AB
Sustainability Report
The report outlines Immunovia's sustainability approach for the 2023 fiscal year, focusing on Public Welfare, Sustainable Products, and a Sustainable Workplace. Following a significant restructuring and the withdrawal of its IMMray PanCan-d test, the company is now focused on developing a next-generation blood test for early pancreatic cancer detection. Immunovia emphasizes collaboration with external partners and research centers to advance its diagnostic capabilities. The report also highlights the company's commitment to ethical business practices and alignment with the UN Sustainable Development Goals.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Published
Apr 29, 2024
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees